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INTRODUCTION
Breast cancer is the third most common cancer in women worldwide and 
accounts for the highest morbidity and mortality (1). Annually 910,000 new 
patients are diagnosed of breast cancer and 376,000 women die from the dis-
ease (2-4). According to the Registry for Malignant Neoplasms of Vojvodina, 
about 9000 women were diagnosed with breast cancer and 4800 died from 
the disease from 1995 to 2004 (5). Based on epidemiological studies, it has 
been established that risk factors for breast cancer include age, reproductive 
events (menarche, menopause, pregnancy), exogenous hormones (oral con-
traceptive and hormone replacement therapy), lifestyle risk factors (alcohol, 
diet, obesity) as well as genetic factors (high- and low-penetrance breast can-
cer susceptibility genes) among others (3,4). The increasing global incidence 
of breast cancer emphasizes the need to understand the various mechanisms 
involved in breast tumor genesis.
A rapid increase in the turnover of malignant cells modulates the enzymes 
level in the blood circulation (6). In addition, enzymatic changes reflect 
the overall changes in metabolism that occur in malignancy (7). Increased 
anaerobic glycolysis and activity of antioxidant enzymes were shown to be 
characteristics of cancer cell metabolism (6,8)
Lactate dehydrogenase (LDH) is released into the surrounding medium at 
an increased rate when cells replicate more rapidly (7,9). It was shown that 
LDH levels were higher in malignant than in normal tissue (10). LDH activity 
correlates with tumor mass or prognosis in human breast cancer. Metastatic 
breast cancer frequently exhibits elevated level of LDH as compared to 
normal breast tissue, but this observation is not consistent and still remains 
controversial (7,9).
Reactive oxygen species (ROS)-induced cell damage has been implicated 
in malignant transformation (11). The formation of free radicals is physi-
ologically prevented or scavenged by host antioxidative defense mechanisms. 
Low levels of essential antioxidants in the circulation have been associated 
with an increased risk of cancer (12). Previously, impairment in antioxidant 
defense mechanisms has been demonstrated in a wide variety of malignan-
cies including breast cancer (13-16). Basic and clinical studies showed that 
over-expression of manganese containing superoxide dismutase (MnSOD) 
may lead to changes of superoxide anion radical/ hydrogen peroxide (O2
.- / 
H2O2) balance causing changes in the cell redox state. Changes in cell redox 
state affects signal transduction pathways that modulate cell proliferation 
(17-19). Over-expression of Cu,ZnSOD also significantly decreases growth 
and survival of breast cancer cells (14). Therefore, it is suggested that both 
MnSOD and Cu,ZnSOD can act as a tumor suppressors (14,20). On the other 
hand, some studies have reported correlation between high MnSOD level and 
invasiveness of breast cancer (20-23).
In the present study, we evaluated LDH and superoxide dismutase (SOD) 
activity in the circulation of patients with breast cancer. This is a preliminary 
report of results from the study on 14 newly diagnosed breast cancer patients 
obtained immediately after surgical intervention and before any adjuvant 
therapy.
PATIENTS AND METHODS
Fourteen recently diagnosed women with breast cancer, median age 43 
[30-49] from Institute of Oncology of Vojvodina, Serbia, were included in the 
study. They underwent surgical treatment and none of them was treated by 
hormonal, chemotherapy or radiotherapy. Patients’ characteristics are shown 
in Table 1. Two out of 14 patients were at clinical stage I, five were classified 
as stage IIA, six as stage IIA, and one as stage IIIB. Informed consent was 
obtained from all the patients and local ethical board approved the study.
Blood samples were obtained from patients between the first and the 
second week after surgical treatment by venepuncture in tubes with EDTA. 
Plasma was separated by centrifugation at 3500 g for 10 min (Megafuge 
1.0 R, Heraeus, Germany). After separation of plasma, the buffy coat was 
removed and the packed cells washed three times with physiologic saline, 
and centrifuged at 3500 g for 10 min. A known volume of erythrocytes was 
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lysed with distillated water. Biochemical estimation for LDH was carried out 
immediately on ECTACHEM 250 apparatus according to original prescription 
by The Orthoclinical Jonhson & Jonhson (USA) producer. 
Samples for SOD analysis were stored at -800C until analysis (less than 1 
month).
Erythrocyte SOD activity was assayed using the spectrophotometric indirect 
inhibition technique of Misra and Fridovich, based on the ability of SOD to 
inhibit auto-oxidation of adrenalin to adrenochrome at alkaline pH (24).
Statistical analysis
Data for biochemical analyses are expressed as individual and median values. 
RESULTS
Individual values of LDH and SOD activity for all 14 breast cancer patients are 
shown in Table 2. Median values of LDH and SOD were 6.73 [5.12 - 11.00] 
(μkat/L) and 3.00 [0.87 - 8.45 ] (U/mg Hb) respectively.
LDH activity was in the normal range in all but one breast cancer patient. 
LDH activity in patient at clinical stage IIIB was approximately 2 fold higher 
compared to LDH values in lower stage samples (Table 2, Figure 1).
SOD was 2 to 8 fold increased in 11 patients in comparison to median physiologi-
cal range for erythrocytes (27-29). Both patients at clinical stage I had the highest 
(~8 fold increased) level of SOD (Table 2, Figure 2). Significant individual differ-
ences in SOD activity were present in patients at IIA and IIB stage of disease.
Table 2. Activities of LDH and SOD in circulation of breast cancer patients
No Age Clinical stage
LDH*
(μkat/L)
 SOD*
 (U/mg Hb)
1 30 I 6.98 8.45
2 47 I 6.70 7.81
3 39 IIA 6.50 3.38
4 43 IIA 6.76 3.12
5 43 IIA 6.12 0.87
6 35 IIA 6.89 2.59
7 45 IIA 6.07 2.54
8 43 IIB 6.76 3.76
9 32 IIB 5.12 4.96
10 43 IIB 6.23 0.98
11 49 IIB 6.49 1.02
12 44 IIB 8.54 1.88
13 39 IIB 6.75 4.00
14 35 IIIB 11.00 2.88
*Ref. values: LDH: 5.22-10.30 μkat/L; SOD: 0.8-1 U/mg Hb (25-29).
DISCUSSION
In this preliminary study, we investigated the activity of serum lactate dehydro-
genase and superoxide dismutase in erythrocytes of patients with breast cancer. 
This investigation is a part of screening study dealing with effects of chemo-
therapy on antioxidative status and chromosomal damages in breast cancer 
patients. Results showed that only patient at clinical stage IIIB without distant 
metastases at the time of investigation had an increased LDH activity. Clinical 
follow-up of that patient showed relapse of primary disease with massive bone 
metastases and lethal outcome one year after ending of the chemotherapy. This 
result suggested that elevated level of LDH might be a prognostic sign of disease 
progression, which is in correlation with investigations of Seth et al. (7). 
Table 1. Characteristics of patients with breast carcinoma included in the study
No
TNM
class.
Clinical stage Type of surgery Hystological type
1 T1N0M0 I Mastectomy Lobular Carcinoma 
2 T1N0M0 I
Breast conserving 
surgery
Lobular Carcinoma
3 T1N1M0 IIA
Breast conserving 
surgery
Lobular Carcinoma
4 T2N0M0 IIA
Breast conserving 
surgery
Medullar Carcinoma 
5 T2N0M0 IIA Mastectomy Ductal Carcinoma 
6 T2N0M0 IIA
Breast conserving 
surgery
Ductal Carcinoma
7 T2N0M0 IIA Mastectomy Ductal Carcinoma
8 T2N1M0 IIB Mastectomy Ductal Carcinoma
9 T2N1M0 IIB
Breast conserving 
surgery
Ductal Carcinoma
10 T2N1M0 IIB Mastectomy Ductal Carcinoma
11 T2N1M0 IIB
Breast conserving 
surgery
Mucinous Carcinoma
12 T2N1M0 IIB Mastectomy Ductal Carcinoma
13 T2N1M0 IIB Mastectomy Ductal Carcinoma
14 T4N1M0 IIIB Mastectomy Ductal Carcinoma
Figure 1. Activities of LDH in the serum of patients with breast cancer
Figure 2. Activities of SOD in erythrocytes of patients with breast cancer
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Total LDH activity is elevated in the serum of about 65% cancer patients 
with metastases in the liver and in 20-60% cancer patients without hepatic 
metastases (25). LDH has also been found to correlate with tumor mass or 
prognosis in human breast cancer (7,30). Ryberg et al. reported that about 
73% of breast cancer tissues had elevated serum LDH levels (30). According 
to Mehreen, LDH was not increased in patients without metastases (9), and 
we found normal LDH values in 13 samples in our screening investigation.
We found 2 to 8 fold increase of SOD in 11 patients in comparison to physi-
ological level in erythrocytes (27-29). Both patients at clinical stage I had the 
highest (~8 fold increased) level of SOD.
The enzymatic antioxidant profile in the circulation of breast cancer patients 
shows an increase in SOD and GSH-Px activities compared with normal 
subjects, whereas the CAT activity showed a significant decrease compared 
with the respective controls (31). Decreased SOD in erythrocytes of patients 
with breast cancer has also been reported (27). Portakal et al. found that total 
SOD activity in breast tumor tissues was significantly higher than that in cor-
responding cancer-free tissues (32). Our findings are in accordance with that 
of Ray et al who reported that SOD activity was significantly raised in eryth-
rocytes of breast cancer patients (16). Oxidative environment in newly estab-
lished malignant phenotype may provoke oxidants to activate gene expression 
through the antioxidant responsive elements (33-35). It is supposed that over-
expression of MnSOD, and probably, Cu,ZnSOD are important components of 
antioxidative defense through the process of malignant transformation (14). 
These facts might explain strongly enhanced SOD activity at lower stage of 
malignant disease that we found in two patients at clinical stage I. 
In conclusion, lactate dehydrogenase and superoxide dismutase activity might 
be useful in clinical follow up of breast cancer patients.
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